Facilities & Capacity
thumbnail
Facilities & CapacityBolt Bio cuts workforce by 50% to refocus pipelineBolt Bio cuts workforce by 50% to refocus pipeline
Bolt Biotherapeutics outlined plans to halve its workforce as part of a “strategic refocusing” that will see the firm stop development of antibody conjugate candidate trastuzumab imbotolimod.